ArticleFrontiers in cardiovascular medicine2025
Association of SMuRFs with cardiovascular risk factors, disease burden, and pharmacological management in Middle Eastern patients with ASCVD and a family history of premature CVD.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06199869 (Absence of Standard Modifiable Risk Factors Among 5000 Middle Eastern Patients With Atherosclerotic Cardiovascular Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Absence of Standard Modifiable Risk Factors Among 5000 Middle Eastern Patients With Atherosclerotic Cardiovascular Disease: Clinical Profiles and Prevalence of Other Risk Factors and Comorbidities
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cardiovascular diseases (CVDs) are considered the main reason for death around the world Methods: We analyzed data from six established cardiovascular registries and the Jordan SMuRF-less cohort study. All datasets were integrated into a single harmonized database to ensure consistency in variable definitions and measurement. The combined dataset included standardized information on participants' demographic and clinical characteristics, cardiovascular risk factors, comorbidities, medication use, and one-year outcomes among individuals categorized as having 0, 1-2, or 3-4 Standard Modifiable Risk Factors (SMuRFs). In total, data from 1,859 participants with atherosclerotic cardiovascular disease (ASCVD) and a family history of early cardiovascular disease were included in the final analysis. Results: Age varied among the groups. The youngest group (G1) had a mean age of 51.9 ± 12.7 years, while the oldest group (G3) had a mean age of 57.1 ± 10.1 years ( Conclusion: The study highlights the significant impact of SMuRFs on cardiovascular health. Older patients with a higher burden of SMuRFs show worse lipid profiles and increased medication use. Given the high prevalence of metabolic syndrome and diabetes in the region, targeted interventions, including lifestyle changes and early pharmacological management, are essential for reducing CVD risk in Middle Eastern populations. Clinical Trial Registration: ClinicalTrials.gov, NCT06199869.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.